Cambiar Aggressive Value ETF
Limited financial coverage for CAMX.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The Cambiar Aggressive Value Exchange Traded Fund maintains a highly focused and undiversified investment portfolio, comprising Cambiar's top-rated investment ideas. The fund's main objective is to achieve significant capital growth over an extended period. It is specifically constructed to exhibit a substantial active share and serve as a source of outperformance within a broader asset allocation strategy.
- IPO
- 2023
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on CAMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $63.31M
- Div Yield
- 1.69%
- 52W High
- $36.30
- 52W Low
- $29.89
- 50D MA
- $34.97
- 200D MA
- $33.72
- Beta
- 0.82
- RSI (14)
- 44
- Avg Volume
- 342
No earnings-call transcripts are available for CAMX yet.
- Free Float
- 0.0%
- Shares Outstanding
- 1.87M
- Float Shares
- 0
of shares held by institutions
10 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cambiar Investors LLC | 397.67K | 0 |
| Cdkv Holdings LLC | 18.33K | ▼ 826 |
| Kohmann Bosshard Financial Services, LLC | 11.48K | 0 |
| Waddell & Associates, LLC | 10.60K | 0 |
| Advisory Advocates, LLC | 8.17K | 0 |
| Jane Street Group, LLC | 7.00K | ▲ 7.00K |
| Ubs Group AG | 355 | ▲ 161 |
| Mercer Global Advisors Inc /Adv | 242 | ▲ 242 |
| Morgan Stanley | 118 | 0 |
| Key Financial Inc | 44 | 0 |
Our CAMX coverage
Recent articles, reports, and earnings notes.
No research on CAMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CAMX report →Albany Engineered Composites to Showcase Advanced Composite Solutions at CAMX 2026
businesswire.com · Aug 24
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
prnewswire.com · Jan 9
Delta Earnings Showcase 2025 Worries & Active ETF Opportunities
etftrends.com · Apr 9
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
prnewswire.com · Jul 15
Bull vs. Bear: Value Investing Status — “It's Complicated”
etftrends.com · Apr 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.